From the upcoming September edition of Repertoire Magazine. August 20, 2020 - Designed to meet the evolving and critical needs of point-of-care (POC) testing, the BD Veritor Plus system enables you to streamline the testing experience. Be ready for flu season by testing with CLIA-waived Flu A+B, Group A Strep, and respiratory syncytial virus (RSV) assays along with the … [Read more...]
BD announces $24M U.S. government investment to support scale up of U.S. manufacturing of COVID-19 diagnostic tests
July 31, 2020 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced a $24 million investment from the U.S. Department of Defense (DOD) in collaboration with the U.S. Department of Health and Human Services (HHS) to support the scale up of U.S. manufacturing capabilities for BD Veritor Solution for Rapid Detection of SARS-CoV-2 (the virus that causes … [Read more...]
BD launches next-gen microbiology solution for liquid, non-liquid sample processing
July 28, 2020 - BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced it has received CE mark approval for the new BD Kiestra InoqulA system powered by BD Synapsys informatics solution. The BD Kiestra InoqulA is available as a standalone instrument for microbiology labs. The company says the device is “a high throughput solution that offers enhanced workflow … [Read more...]
BD receives FDA approval for HPV test with extended genotyping capabilities
July 22, 2020 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) received approval for a pre-market approval (PMA) supplement from the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity HPV Assay. The PMA supplement includes the expansion for genotype reporting beyond HPV genotypes 16, 18, and 45 to include types 31, 51, 52, 33/58, … [Read more...]
BD launches rapid point-of-care antigen test to detect COVID-19 in 15 minutes
BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a rapid, point-of-care, SARS-CoV-2 diagnostic test for use with the company’s BD Veritor Plus System. This new assay delivers results in 15 minutes on an easy-to-use, highly portable instrument, which enables … [Read more...]
BD part of consortium to bring scalable solutions to the pandemic
(March 26, 2020) - A consortium of life sciences companies announced on March 25 a collaboration to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19, according to a release from the Bill & Melinda Gates Foundation. “The life sciences industry brings a range of assets, resources, and expertise needed to … [Read more...]